{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:01:43Z","timestamp":1779300103988,"version":"3.51.4"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T00:00:00Z","timestamp":1490572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100008568","name":"Norske Kvinners Sanitetsforening","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2017,5]]},"abstract":"Abstract<\/jats:title>Introduction<\/jats:title>After premenopausal risk\u2010reducing salpingo\u2010oophorectomy (RRSO<\/jats:styled-content>) to prevent ovarian cancer, the non\u2010cancer\u2010related morbidity and mortality may be increased if sex hormones are not replaced. Several guidelines recommend systemic hormone replacement therapy (HRT<\/jats:styled-content>) to these women until the expected age of menopause. We aimed to study the use of HRT<\/jats:styled-content> after RRSO<\/jats:styled-content>.<\/jats:p><\/jats:sec>Material and methods<\/jats:title>Participants were 324 women after RRSO<\/jats:styled-content> and 11 160 postmenopausal controls. A subsample of 950 controls had undergone bilateral salpingo\u2010oophorectomy (BSO<\/jats:styled-content>). All participants completed the same questionnaire regarding HRT<\/jats:styled-content> use. We compared HRT<\/jats:styled-content> use in the RRSO<\/jats:styled-content> group with the BSO<\/jats:styled-content> controls using logistic regression.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the women aged \u226452 years without a history of breast cancer, 51.7% of the RRSO<\/jats:styled-content> group and 48.7% of the BSO<\/jats:styled-content> controls reported current use of systemic HRT<\/jats:styled-content> (odds ratio 1.13, 95% confidence interval 0.72\u20131.76). Among the HRT<\/jats:styled-content> users, systemic estrogen was used by 35.1% and 58.7% in the RRSO<\/jats:styled-content> and BSO<\/jats:styled-content> control groups, respectively (p<\/jats:italic> = 0.001). Among the women aged >52 years, 16.8% of the RRSO<\/jats:styled-content> group and 38.4% of the BSO<\/jats:styled-content> controls (p<\/jats:italic> < 0.001) used systemic HRT<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Among the RRSO<\/jats:styled-content> women and BSO<\/jats:styled-content> controls \u226452 years old without a history of breast cancer, relatively few were current users. If there are no contraindications, these women would benefit from systemic HRT<\/jats:styled-content>. Additionally, almost 40% of the BSO<\/jats:styled-content> controls >52 years used systemic HRT<\/jats:styled-content>. Doctors should be aware of this practice and prescribe systemic HRT<\/jats:styled-content> when indicated.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aogs.13120","type":"journal-article","created":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T07:52:42Z","timestamp":1488009162000},"page":"547-555","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Use of hormone replacement therapy after risk\u2010reducing salpingo\u2010oophorectomy"],"prefix":"10.1111","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-400X","authenticated-orcid":false,"given":"Nora","family":"Johansen","sequence":"first","affiliation":[{"name":"Department of Gynecology S\u00f8rlandet Hospital Arendal Arendal Norway"},{"name":"Research Unit S\u00f8rlandet Hospital Arendal Norway"},{"name":"Faculty of Medicine University of Oslo Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid H.","family":"Liavaag","sequence":"additional","affiliation":[{"name":"Department of Gynecology S\u00f8rlandet Hospital Arendal Arendal Norway"},{"name":"Research Unit S\u00f8rlandet Hospital Arendal Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole\u2010Erik","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Clinical Science University of Bergen Bergen Norway"},{"name":"Department of Gynecology and Obstetrics Haukeland University Hospital Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"D\u00f8rum","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology Oslo University Hospital Radiumhospitalet University of Oslo Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonje","family":"Braaten","sequence":"additional","affiliation":[{"name":"Institute of Community Medicine University of Troms\u00f8 Troms\u00f8 Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trond M.","family":"Michelsen","sequence":"additional","affiliation":[{"name":"Research Unit S\u00f8rlandet Hospital Arendal Norway"},{"name":"Division of Gynecology and Obstetrics Department of Obstetrics Oslo University Hospital Rikshospitalet Oslo Norway"},{"name":"Norwegian National Advisory Unit on Women's Health Oslo University Hospital Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21536"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.1066"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.2.185"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn442"},{"key":"e_1_2_9_6_1","unstructured":"National Comprehensive Cancer Network.Clinical Practice Guidelines in Oncology. Genetic\/Familial High\u2010Risk Assessment: Breast and Ovarian update 11\/16.2016. Available online at:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf(accessed November 1 2016)."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.202"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.12.326"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1896"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.11.016"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e31818888f7"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182864350"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000276984.19542.e6"},{"key":"e_1_2_9_14_1","unstructured":"The Norwegian Guidelines of Gynecologic Oncology: Ovarian\u2010 tubal\u2010 and peritoneal cancer update 01\/15\/2016. Available online at:http:\/\/legeforeningen.no\/Fagmed\/Norsk-gynekologisk-forening\/Veiledere\/Veileder-gynekologisk-onkologi\/Eggstokk-tube-bukhinnekreft\/(accessed June 10 2016)."},{"key":"e_1_2_9_15_1","unstructured":"Australasian Menopausal Society.Menopause management: surgical menopause update 05\/13\/2013. Available online at:http:\/\/www.menopause.org.au\/for-women\/information-sheets\/736-surgical%20-menopause(accessed August 15 2016)."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e31824b970a"},{"key":"e_1_2_9_17_1","unstructured":"National Institute for Health and Care Excellence.Familial breast cancer: classification care and managing breast cancer and related risks in people with a family history of breast cancer. Recommendations update 06\/13\/2013. Available online at:https:\/\/www.nice.org.uk\/guidance\/cg164\/chapter\/1-recommendations(accessed August 30 2016)."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:CACO.0000007982.18311.2e"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6874-8-1"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2015.12.004"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn058"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji071"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.8151"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn313"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.3449"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-10858-7_10"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1820"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/13697130903009195"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2217\/WHE.12.41"},{"key":"e_1_2_9_31_1","volume-title":"AHRQ comparative effectiveness reviews. Menopausal symptoms: comparative effectiveness of therapies","author":"Grant MD","year":"2015"},{"key":"e_1_2_9_32_1","unstructured":"Cancer in Norway. Cancer Statistics: FEMALES Number of new cases by primary site and year 2006\u20102015. Update 11\/16. Available online at:https:\/\/www.kreftregisteret.no\/Registrene\/Kreftstatistikk\/(accessed November 17 2016)."},{"key":"e_1_2_9_33_1","unstructured":"Statistics Norway. Population. Update 11\/16. Available online at:http:\/\/www.ssb.no\/en\/befolkning\/nokkeltall(accessed January 12 2016)."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28677"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.13.0649"},{"key":"e_1_2_9_36_1","unstructured":"Norwegian Institute of Public Health: Drug consuption. Genito urinary system and sex hormones: Sales of product with estrogen (G03C and G03F) 1990\u20102015.2016. Available online at:http:\/\/www.legemiddelforbruk.no\/atc\/ATC_group_G.pdf(accessed September 13 2016)."},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0375-4"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e31818ffe28"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faogs.13120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aogs.13120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T04:59:28Z","timestamp":1696481968000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/aogs.13120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,27]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/aogs.13120"],"URL":"https:\/\/doi.org\/10.1111\/aogs.13120","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,27]]},"assertion":[{"value":"2017-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}